|
WO2019018975A1
|
|
Inhibitors of ror gamma
|
|
CN109743875A
|
|
The inhibitor of MENIN-MLL interaction
|
|
TW201734001A
|
|
Modulators of ROR-gamma
|
|
CN108779116A
|
|
The inhibitor of Multiple Endocrine tumor albumen-MLL interactions
|
|
CN108463458A
|
|
The conditioning agent of ROR- γ
|
|
US9481674B1
|
|
Dihydropyrrolopyridine inhibitors of ROR-gamma
|
|
US2016122318A1
|
|
Isoindoline inhibitors of ROR-gamma
|
|
US2016122345A1
|
|
Dihydropyrrolopyridine inhibitors of ROR-gamma
|
|
US2016113930A1
|
|
Compounds for use in treating rett syndrome
|
|
EA031967B1
|
|
Dihydropyrrolopyridine inhibitors of ror-gamma
|
|
KR20170032468A
|
|
Piperazine derivatives as liver x receptor modulators
|
|
US2017231992A1
|
|
Compounds for use in treating acute coronary syndrome and related conditions
|
|
US2017044203A1
|
|
Purine derivatives as CD73 inhibitors for the treatment of cancer
|
|
US2015250787A1
|
|
Compounds for use in treating skin cancers
|
|
CN105940002A
|
|
Dihydropyrrolopyridine inhibitors of ROR-gamma
|
|
EP2991994A1
|
|
Thiazolopyrrolidine inhibitors of ror-gamma
|
|
US2015259325A1
|
|
Inhibitors of β-secretase
|
|
CN104203951A
|
|
Liver x receptor modulators
|
|
ME02660B
|
|
Liver x receptor modulators
|
|
AU2011244858A1
|
|
Renin inhibitors
|
